open navigation
New evidence supports Gocap: it objectively assesses the insulin adherence of people with diabetes, and adherence is associated with their glycemic control.
Ms. Gvazdauskas has thirty years of commercial leadership experience in consumer, pharmaceutical, and medical device industries, and a history of building and leading successful teams in big pharma as well as early stage companies.
A member of Common Sensing's board of directors since November of 2015 and Chief Operating Officer since January 2018, Kevin is excited to play an expanded role in Common Sensing's growth.
Common Sensing has signed a design service agreement with Sketch-to-Scale™ solutions provider Flex Ltd. The health solutions group at Flex will help redesign Gocap™: the first smart cap that can turn existing injector pens into smart injectors.
Haselmeier and Common Sensing announced a partnership agreement to develop smart connected monitoring and support solutions for users of injectable medicines. The combined injector pen-Gocap platform will record the time and amount of every injector dose, along with other information like storage temperature.